PX 102

Drug Profile

PX 102

Alternative Names: Px-102; Px20606

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phenex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Metabolic syndrome; Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Oct 2012 Phenex Pharmaceuticals completes a phase I trial in Healthy volunteers in Germany (NCT01998672)
  • 01 Feb 2012 Phenex Pharmaceuticals initiates enrolment in a phase I trial for Healthy volunteers in Germany (NCT01998672)
  • 01 Dec 2011 Phenex Pharmaceuticals completes a phase I trial in Healthy volunteers in Germany (NCT01998659)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top